Investor Relations

Profound Medical is based in Mississauga, Canada and was founded in 2008. It started as a medical device company that has developed ground-breaking technology in the area of localized prostate cancer.

The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform, and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE marked and Profound Medical is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions.  The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO® in the United States.

Profound Medical is also commercializing Sonalleve MR-HIFU an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The Company is also in the early stages of exploring additional potential treatment markets for Sonalleve MR-HIFU, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.

Profound Medical ‘s common shares are traded on the TSX Venture Exchange under ticker symbol “PRN”.  The company’s financial statements can be found on SEDAR.

Newsroom

2017

Profound Medical Corp. to Present at he 29th Annual Piper Jaffray Healthcare Conference
November 14, 2017, Press Release

Profound Medical Corp. Announces Third Quarter 2017 Financial Results
November 7, 2017, Press Release

Profound Medical Corp. Announces Expanded Clinical Use of TULSA-PRO® in Prostate Care to Include BPH
November 6, 2017, Press Release

Profound Medical Corp. to present at the 2017 Canaccord Genuity Medical Technologies & Diagnostics Form
October 26, 2017, Press Release

Profound Medical Corp. to Release Third Quarter 2017 Financial Results on    November 7, 2017 – Conference Call to Follow
October 25, 2017, Press Release

Profound Medical Corp. Announces Closing of $10 Million “Bought Deal” Financing
September 20, 2017, Press Release

Prostate cancer cure: Pinckney man part of breakthrough study
September 20, 2017, LivingstonDaily

Profound Makes Leap to Platform Company from Prostate Product
September 5, 2017, BioTuesdays

Profound Medical Corp. Announces $10 Million “Bought Deal” Financing
August 24, 2017, Press Release

Profound Medical Announces Second Quarter 2017 Financial Results
August 23, 2017, Press Release

Profound Medical Corp. to Release Second Quarter 2017 Financial Results on August 23, 2017 – Conference Call to Follow
August 9, 2017, Press Release

Groundbreaking Prostate Cancer Study Enters Its Final Phase
August 7, 2017, Beaumont Health, News Release

Profound Medical Corp. Completes Acquisition of Royal Philips’ Sonalleve MR-HIFU Business
July 31, 2017, Press Release

Profound Medical Corp. Announces Definitive Agreement with Royal Philips to Expand Collaboration and Acquire Sonalleve MR-HIFU Business
June 30, 2017, Press Release

First Hoosier prostate cancer patients treated with MRI-guided transurethral ultrasound
June 7, 2017, Indiana University School of Medicine – Research Updates

Profound Medical Corp. Announces Annual Meeting of Shareholders Voting Results
May 24, 2017, Press Release

Profound Posts First-time Revenue in Q1; TACT trial 25% enrolled
May 9, 2017, BioTuesdays

Profound Medical Corp. Announces First Quarter 2017 Financial Results
May 9, 2017, Press Release

Profound Medical to Present at the CIBC Technology & Innovation Conference 5.0
May 3, 2017, Press Release

Profound Medical Corp. to Release First Quarter 2017 Financial Results on May 9, 2017 – Conference Call to Follow
April 25, 2017, Press Release

Profound Medical Corp. Obtains DTC Eligibility for its Common Shares in the U.S.
April 18, 2017, Press Release

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth
March 28, 2017, BioTuesdays

Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO® System
March 27, 2017, Press Release

Profound Medical Corp. Announces Management Change
March 24, 2017, Press Release

Profound Medical Corp. and Philips Announce first TULSA-PRO® Sale in Finland to Turku University Hospital
March 20, 2017, Press Release

OTC Market Groups Welcomes Profound Medical to OTCQX
March 13, 2017, OTC Press Release

Profound Medical Corp. to Begin Trading on OTCQX on March 13, 2017
March 9, 2017, Press Release

Profound Medical Corp. Announces Fourth Quarter and Full Year 2016 Financial Results
March 6, 2017, Press Release

Profound Medical Corp. to Release Fourth Quarter and Full Year 2016 Financial Results on March 6, 2017 – Conference Call to Follow
February 21, 2017, Press Release

Profound Medical to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
February 14, 2017, Press Release

Profound Medical Announces Special Meeting of Shareholders Voting Results
January 26, 2017, Press Release

Kenneth Galbraith joins Profound Medical Board
January 18, 2017, BioTuesdays

Profound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors
January 17, 2017, Press Release

2016

Profound Medical Corp.  Announces Third Quarter 2016 Financial Results
November 16, 2016, Press Release

Profound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares
November 14, 2016, Press Release

Profound Medical Corp. to Present at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum
November 3, 2016, Press Release

Profound Medical Corp. to Present at the Stifel 2016 Healthcare Conference
November 1, 2016, Press Release

Profound Medical Corp. to Release Third Quarter 2016 Financial Results on November 16, 2016 – Conference Call to Follow
October 26, 2016, Press Release

Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
October 17, 2016, Press Release

Profound Medical Receives Frost & Sullivan’s 2016 New Product Innovation Award
October 5, 2016, Press Release

Profound Medical Corp. Announces First Patient Treated in TACT Pivotal Clinical Trial at Vanderbilt University Medical Center
September 22, 2016, Press Release

New to the Neighbourhood: Profound Medical comes to Mississauga
September 1, 2016, Biotechnology Focus

Profound Medical Corp. Announces Second Quarter 2016 Financial Results
August 18, 2016, Press Release

Profound Medical names Arun Menawat as CEO
August 16, 2016, BioTuesdays

Profound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy
August 15, 2016, Press Release

Mackie starts Profound Medical at speculative buy
August 10, 2016, BioTuesdays

Profound Medical Corp., to Release Second Quarter 2016 Financial Results on August 18, 2016
August 10, 2016, Press Release

Profound Medical Corp., Announces Annual Meeting of Shareholders Voting Results
June 22, 2016, Press Release

Profound Medical Corp., and Philips sell TULSA-PROTM System to University Hospital of Cologne, Germany
June 21, 2016, Press Release

Profound Medical Corp., and Philips sell TULSA-PROTM System to UCL and UCLH
June 20, 2016, Press Release

Revolutionizing Prostate Cancer Treatment, investinontario.com
June  2016, investinontario.com

Profound Medical Corp. to hold Annual General Meeting of the Shareholders
June 7, 2016, Press Release

FDA Grants Profound Medical Corp. IDE Approval for TULSA-PROTM
May 19, 2016, Press Release

Profound Medical Corp  and Philips Sign Sales and Marketing Agreement in MRI -guided therapy in Prostate Cancer Care
May 11, 2016, Press Release

Profound Medical Corp  Announces First Quarter 2016 Financial Results
May 6, 2016, Press Release

Profound Medical Corp. to Present at Upcoming Conference 
April 29, 2016, Press Release

Profound Medical  Corp. to Release First Quarter 2016 Financial Results on May 6, 2016 
April 29, 2016, Press Release

Profound Medical Corp. Announces World’s First Sale of TULSA-PRO for Prostate Ablation
April 28, 2016, Press Release

Profound Earns European Approval for Prostate Device
April 22, 2016, Focused Ultrasound Foundation

GMP starts Profound Medical at speculative buy
April 13, 2016, BioTuesdays

Profound Medical Corp.  Receives CE Mark Approval for TULSA-PRO
April 11, 2016, , Press Release

Profound Medical Corp.  Announces Full Year 2015 Financial Results
March 2, 2016, Press Release

Profound Medical Corp. and Siemens Enter into Strategic Agreement to Further the Development of Prostate Cancer Care
February 29, 2016, Press Release

Profound Medical Corp. to Release Full Year 2015 Financial Results on March 3, 2016
February 25, 2016, Press Release

Profound Medical Corp., Announces Publication in European Urology
January 8, 2016, Press Release

2015

Profound Medical named 2016 Life Science Company of the Year
November 27, 2015, Press Release

A Brighter Future: Advancements in Prostate Cancer Therapy Minimize Side Effects for Patients
November 20, 2015, Media Planet Supplement, Toronto Star

Profound Medical Corp. Announces Departure of CFO
November17, 2015, Press Release

Profound Medical Corp. Announces Third Quarter 2015 Financial Results
November 5, 2015, Press Release

Hartmut Warnken joins Profound Medical as Vice President, International Sales
November 2, 2015, Press Release

Profound Medical Corp. to Release Third Quarter 2015 Financial Results on November 4, 2015
October 28, 2015, Press Release

Profound Medical to Present at Upcoming Investor Conferences
October 21, 2015, Press Release

Profound Medical Presents Successful 12-Month Phase 1 Outcomes at the European Symposium on Focused Ultrasound Therapy
October 15, 2015, Press Release

Profound Medical to present 12-month outcomes of Phase 1 Clinical Trial at European Symposium on Focused Ultrasound Therapy
October 13, 2015, Press Release

Profound Medical Announces Grant of Share Options
September 18, 2015, Press Release

Profound Medical Corp. Announces Second Quarter 2015 Financial Results
August 25, 2015, Press Release

Profound Medical Corp. Announces First Quarter 2015 Financial Results of Profound Medical Inc.
July 29, 2015, Press Release

Philips and Profound Medical Collaborate to Advance Treatment for Prostate Cancer Patients
July 21, 2015, Press Release

Profound Medical Corp. Announces Annual Meeting of Shareholders Voting Results
June 23, 2015, Press Release

Profound Medical Opens the Market
June 15, 2015, Press Release

Profound Medical Goes Public via Reverse Takeover
June 1, 2015, Biotechnology Focus

Profound Medical Corp. Announces Closing of Qualifying Transaction
June 4, 2015, Press Release

Profound Medical seeking CE Mark for TULSA-PRO This Year
May 26, 2015, Bio Tuesdays

Profound Medical and Shopify show Contrasting Ways to go Public
May 25, 2015, Financial Post

Mira IV Acquisition Corp. Announces Filing of Filing Statement
May 25, 2015, News Release

Preclinical safety and feasibility with 28-day follow-up
May 2015, Journal of Urology, Vol. 192

PMI Announces Going-Public Transaction and Concurrent $28 Million Financing to Fund Next Stage of Growth
April 30, 2015, News Release

Mira IV Acquisition Corp. Announces entering into of an Amalgamation Agreement with PMI
April 29, 2015, News Release

investor-relations

Clinical Publications

Investor Presentations

Financial Statements

Investor Relations Contact

seperator-profound-sm

Stephen Kilmer, Investor Relations
skilmer@profoundmedical.com
647.872.4849

Subscribe

To receive financial information via email, please complete this form;